{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.4857","value":"3.232"},{"groupId":"OG001","spread":"10.0101","value":"-4.242"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Physical functioning: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.7140","value":"-3.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Physical functioning: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.1989","value":"5.051"},{"groupId":"OG001","spread":"16.3608","value":"-3.030"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Role functioning: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.7851","value":"8.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Role functioning: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.6602","value":"7.744"},{"groupId":"OG001","spread":"17.9083","value":"6.061"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Emotional functioning: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.8926","value":"12.500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Emotional functioning: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.9571","value":"5.556"},{"groupId":"OG001","spread":"13.8535","value":"1.515"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Cognitive functioning: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5702","value":"16.667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Cognitive functioning: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.9039","value":"8.586"},{"groupId":"OG001","spread":"18.8025","value":"-7.576"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Social functioning: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.3553","value":"8.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Social functioning: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.4155","value":"5.556"},{"groupId":"OG001","spread":"10.4205","value":"1.515"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Global Health Status/QoL: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"-16.667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Global Health Status/QoL: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.7084","value":"-7.239"},{"groupId":"OG001","spread":"13.8939","value":"-2.020"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Fatigue: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"11.111"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Fatigue: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.1799","value":"-4.545"},{"groupId":"OG001","spread":"7.7850","value":"-4.545"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Nausea & Vomiting: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Nausea & Vomiting: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.4850","value":"-8.586"},{"groupId":"OG001","spread":"10.0504","value":"-3.030"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Pain: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5702","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Pain: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.6134","value":"-3.030"},{"groupId":"OG001","spread":"27.7070","value":"3.030"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Dyspnoea: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Dyspnoea: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.3523","value":"0.000"},{"groupId":"OG001","spread":"29.1288","value":"6.061"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Insomnia: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.1405","value":"33.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Insomnia: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4639","value":"-8.081"},{"groupId":"OG001","spread":"21.5557","value":"9.091"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Appetite loss: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Appetite loss: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.6339","value":"0.000"},{"groupId":"OG001","spread":"14.9071","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Constipation: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0000","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Constipation: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.1499","value":"-12.121"},{"groupId":"OG001","spread":"27.7070","value":"-3.030"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Diarrhoea: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5702","value":"-16.667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Diarrhoea: chg from BL @ wk 120 (n=2,0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.0798","value":"-7.071"},{"groupId":"OG001","spread":"20.1008","value":"6.061"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Financial difficulties: chg from BL @ wk 72 (n=33,11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.7107","value":"-16.667"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Financial difficulties: chg from BL @ wk 120 (n=2,0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"The Quality of Life Questionnaire C30 (QLQ-C30) was developed by the European Organization for Research and Treatment of Cancer (EORTC) to assess quality of life in cancer patients. It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond on a four-point scale from \"not at all\" to \"very much\" for most items. Raw scores are linearly transformed so each score ranged a 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).","dispersionType":"Standard Deviation","groups":[{"description":"* 30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.\n* Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).\n* Concomitant amino acids were given with each administration for kidney protection.\n* 177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.\n* In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed.","id":"OG000","title":"177Lu-DOTA0-Tyr3-Octreotate"},{"description":"* 60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.\n* In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed.","id":"OG001","title":"Octreotide LAR"}],"paramType":"MEAN","populationDescription":"Safety Analysis Set (SAF). Values at Inclusion were taken from last non-missing value prior to randomization (the only scheduled pre-randomization assessment was at the Baseline visit). Calculations at each visit included only participants with scores at the visit and Inclusion.","reportingStatus":"POSTED","timeFrame":"Inclusion (Baseline) (BL), Week 72, Week 120","title":"Change From Baseline in the EORTC QLQ-C30 Questionnaire","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}